Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04677309
Other study ID # THORUS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 20, 2020
Est. completion date April 2023

Study information

Verified date October 2022
Source Hospital General Universitario de Valencia
Contact Ana Broseta Lleó, Consultant
Phone 0034963187554
Email ana.broseta@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to assess whether lung ultrasound is able to detect lung injury after lung resection surgery.


Description:

Postoperative pulmonary complications (PPC) are common after lung resection surgery, with an incidence that ranges between 11-32%. As PPC are associated with worse outcomes, many studies aim to find predictors that identify high risk patients and prompt specific interventions and/or monitoring and hence, improve outcomes. PPC result from lung injury inherent to lung resection surgery. Lung aeration changes seen with lung ultrasound (LUS) could detect lung injury and thus, identify patients at high risk of PPC. The underlying mechanisms of lung injury are different in the dependent and non-dependent lung; oxidative stress in both lungs, lung injury associated with one-lung ventilation in the dependent lung and ischemia/reperfusion or surgical manipulation in the non-dependent lung. LUS evaluates the operated and non-operated lung separately and so it can be valuable in understanding the characteristics and intensity of lung injury in each lung specifically. This is a prospective, single-centre, observational study in which 28 consecutive participants with non-small cell lung cancer scheduled for lobectomy will be recruited. Participants will be divided in two groups depending on the surgical approach. First group will be lobectomy via thoracotomy. Second group will be lobectomy via VATS. Participants will be recruited consecutively until there are 14 patients in each group. LUS will be performed in each participant's dependent and non-dependent lung at three predefined time points: before surgery, after extubation and 24 h after surgery. Each hemithorax will be divided into 6 areas: anterior, lateral and posterior, separated by the anterior and posterior axillary lines, each divided into upper and lower zones. For each echographic examination, cineloops of the most pathological findings in each area will be stored and analysed offline by two independent and blinded anesthesiologists. From these, a semiquantitative score, the modified lung ultrasound score (mLUSS), will be calculated for each hemithorax to assess lung aeration at each time point. The level of agreement for mLUSS will be tested. At the same predefined time points blood plasma samples will be collected, flash-frozen and stored in order to measure levels of the inflammatory mediators IL-6, IL-10 and TNFα. The invertigators hypothesise that LUS can detect lung injury after lung resection surgery. The primary objective of the study is to assess changes in lung aeration after lung resection with mLUSS. Secondary objectives are, first, to describe LUS findings after lung resection surgery, second, to assess the ability of mLUSS to detect oxygenation changes after lung resection and third, to compare the behaviour of inflammatory mediators in plasma with mLUSS changes.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date April 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 - ASA I-III - Non-small cell lung neoplasm - Elective lung resection - Via VATS - Under one-lung ventilation Exclusion Criteria: - pregnancy - Diagnosed pulmonary fibrosis - Scheduled surgery limited to biopsy - Surgery that includes resection of the thoracic wall or the diaphragm - Predicted FEV1 < 40% - Neoplasm metastasis - Obesity class II or more (BMI = 35 kg/m^2) - Risk of malnutrition CONUT > 1 - Hemoglobin < 10 g/dl - Chronic kidney failure: glomerular filtration < 60 ml/min/m^2, nephrectomy, kidney transplantation - Treatment with corticosteroids or immunosuppressive agents 3 months before surgery - Transfusion of blood products during the previous 10 days - Heart failure (New York Heart Association Functional Class 3 or 4) during the week before surgery. - Heart valve diseases over stage B of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 - Diastolic dysfunction

Study Design


Locations

Country Name City State
Spain Hospital General Universitario de Valencia Valencia

Sponsors (2)

Lead Sponsor Collaborator
Ana Broseta Lleó Hospital General Universitario de Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mLUSS after lung resection The modified lung ultrasound score (mLUSS) ranges 0-36; the higher the score, the less aeration (worse). preoperative vs immediate postoperative period vs 24 hours after surgery
Secondary LUS findings in the dependent and non-dependent lung description of LUS findings after lung resection surgery in each lung preoperative vs immediate postoperative period vs 24 hours after surgery
Secondary Changes in oxygenation (PAFI) after lung resection PAFI is the ratio between paO2 and fraction of inspired oxygen; the lower, the worse. preoperative vs immediate postoperative vs 24 hours after surgery
Secondary Changes in plasma cytokine IL-6 after lung resection preoperative vs immediate postoperative vs 24 hours after surgery
Secondary Changes in plasma cytokine IL-10 after lung resection preoperative vs immediate postoperative vs 24 hours after surgery
Secondary Changes in plasma TNFa after lung resection preoperative vs immediate postoperative vs 24 hours after surgery
Secondary Changes in blood bone natriuretic peptide (BNP) after lung resection. preoperative vs immediate postoperative vs 24 hours after surgery
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk